3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
257
Carcinoma, Intraductal, Noninfiltrating
24
Breast Carcinoma In Situ
21
Neoplasms
12
Neoplasm Metastasis
12
Breast Neoplasms, Male
12
Ovarian Neoplasms
10
Inflammatory Breast Neoplasms
7
Glioblastoma
6
Prostatic Neoplasms
5
Endometrial Neoplasms
5
Central Nervous System Neoplasms
5
Gliosarcoma
4
Fallopian Tube Neoplasms
4
Breast Cancer Female
4
Brain Neoplasms
4
Glioma
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Ductal, Breast
3
Breast Diseases
3
Astrocytoma
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Sarcoma
2
Recurrence
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Medulloblastoma
2
Liver Neoplasms
2
Infertility
2
Interventions
Pemetrexed
9
Nivolumab
8
Cisplatin
8
Carboplatin
8
pembrolizumab
7
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
padeliporfin
5
durvalumab
5
Paclitaxel
5
Bevacizumab
5
palbociclib
4
napabucasin
4
atezolizumab
4
Irinotecan
4
Fulvestrant
4
Fluorouracil
4
Cyclophosphamide
4
ribociclib
3
osimertinib
3
cobimetinib
3
alectinib
3
abemaciclib
3
Trastuzumab
3
Sunitinib
3
Radiosurgery
3
Drug Therapy
3
Docetaxel
3
Cetuximab
3
Anastrozole
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms by Site
×
Tamoxifen
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled